Comparison of Pregnancy Outcomes in Primigravida Receiving Low-Dose Aspirin for the Prevention of Preeclampsia.

NCT07852585 | Completed

• 1 other identifier: Dr-Shamsa-QAMC
• Study Type: interventional
• Target: 160
• Locations: 1 country
• Sites: 1

Brief Summary

Local data on the effectiveness of low-dose aspirin in high-risk primigravida are limited. The present study was planned to compare pregnancy outcomes between high-risk primigravida receiving low-dose aspirin (75 mg/day) from 12 weeks of gestation and those not receiving aspirin.

Conditions

Preeclampsia

Outcome Measures

Primary Outcomes (4)

• Preeclampsia

  The frequency of patients developing preeclampsia as new-onset hypertension after 20 weeks of gestation was noted.

  After 24 weeks of the enrollment

• Placental abruption

  The frequency of patients with placental abruption.

  After 24 weeks of the enrollment

• Preterm birth

  The frequency of neonates born before 37 completed weeks was noted.

  At birth, after 24 weeks of the enrollment

• Low-birth-weight

  The frequency of low-birth-weight neonates, defined as a birth weight\<2.5 kg, was noted.

  At birth, after 24 weeks of the enrollment

Study Arms (2)

Aspirin-Group

EXPERIMENTAL

Participants received low-dose aspirin (75 mg) once daily, starting at 12 weeks of gestation and continuing until 36 weeks of gestation or delivery, along with standard care.

Drug: Low-dose aspirin; Other: No-Aspirin

No-Aspirin-Group

EXPERIMENTAL

Participants received standard antenatal care without aspirin.

Other: No-Aspirin

Interventions

Low-dose aspirin DRUG

Participants received low-dose aspirin (75 mg) once daily, starting at 12 weeks of gestation and continuing until 36 weeks of gestation or delivery, along with standard care.

Aspirin-Group

No-Aspirin OTHER

Participants received standard antenatal care without aspirin.

Aspirin-Group; No-Aspirin-Group

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Primigravida women
• High-risk pregnancy
• Aged 18-40 years
• Singleton pregnancy
• Gestational age ≤12 weeks

You may not qualify if:

• Women with pre-existing chronic hypertension
• Renal disease
• Diabetes mellitus
• Autoimmune disease
• Bleeding disorders
• Hypersensitivity to aspirin
• History of peptic ulcer disease
• Those using aspirin or other antiplatelet drugs

Sponsors & Collaborators

• Muhammad Aamir Latif: lead

Study Sites (1)

Bahawal Victoria Hospital/Quaid-e-Azam Medical College

Bahawalpur, Punjab Province, 63100, Pakistan

Location

MeSH Terms

Conditions

Pre-Eclampsia

Interventions

Aspirin; N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Intervention Hierarchy (Ancestors)

Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Officials

• Shamsun Nisa, FCPS

  Bahawal Victoria Hospital/Quaid-e-Azam Medical College Bahawalpur

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Research Consultant

Study Record Dates

• First Submitted: September 25, 2026
• First Posted: October 1, 2026
• Study Start: August 1, 2025
• Primary Completion: June 30, 2026
• Study Completion: June 30, 2026
• Last Updated: October 1, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)